Rapid Reversal of Psychotic Depression Using Mifepristone

@article{Belanoff2001RapidRO,
  title={Rapid Reversal of Psychotic Depression Using Mifepristone},
  author={J. Belanoff and B. Flores and M. Kalezhan and B. Sund and A. Schatzberg},
  journal={Journal of Clinical Psychopharmacology},
  year={2001},
  volume={21},
  pages={516-521}
}
  • J. Belanoff, B. Flores, +2 authors A. Schatzberg
  • Published 2001
  • Medicine
  • Journal of Clinical Psychopharmacology
    • The rationale for treating psychotic major depression with glucocorticoid receptor (GR) antagonists is reviewed. Five patients with psychotic major depression were given 600 mg of mifepristone in a 4-day, double-blind, placebo-controlled crossover study. All the patients completed the protocol and adverse effects were not observed or reported. All of the five patients showed substantial improvements in their Hamilton Rating Scale for Depression scores while they were receiving mifepristone, and… CONTINUE READING
    View on Wolters Kluwer
    ncbi.nlm.nih.gov
    252 Citations
    Highly Influential Citations
    6
    Background Citations
    78
    Methods Citations
    5
    Results Citations
    15

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

      Paper Mentions

      Interventional Clinical Trial
      A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
      Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed… Expand
      ConditionsPsychosis, Psychotic Depression, Severe Major Depression With Psychotic Features
      InterventionDrug
      Corcept Therapeutics
      March 2008 - June 2014
      Blog Post
      COMMERCIAL BIAS at STANFORD and CORCEPT
      Health Care Renewal
      7 August 2008
      Blog Post
      COMMERCIAL BIAS at STANFORD and CORCEPT
      Health Care Renewal
      7 August 2008
      Blog Post
      MANAGING CONFLICTS of INTEREST at STANFORD
      Health Care Renewal
      26 July 2008
      Blog Post
      MANAGING CONFLICTS of INTEREST at STANFORD
      Health Care Renewal
      26 July 2008
      Interventional Clinical Trial
      A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
      Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in… Expand
      ConditionsMajor Depressive Disorder, Psychotic Disorders
      InterventionDrug
      Corcept Therapeutics
      September 2004 - January 2007
      252 Citations
      Citation Type

      Citation Type

      Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
      • 188
      • PDF
      Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression
      • 130
      A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.
      • 41
      Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression
      • 20
      An open label trial of C-1073 (mifepristone) for psychotic major depression*
      • 284
      • PDF
      Efficacy and Safety of Mifepristone for the Treatment of Psychotic Depression
      • 54
      Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response
      • 23
      The use of mifepristone in the treatment of neuropsychiatric disorders
      • 92
      Antidepressant Treatment of Psychotic Major Depression: Potential Role of the σ Receptor
      • 49
      Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications
      • 36

      References

      SHOWING 1-10 OF 34 REFERENCES
      Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.
      • 108
      The Treatment of Psychotic Major Depressive Disorder with Drugs and Electroconvulsive Therapy
      • 76
      Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants.
      • 75
      Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression.
      • 74
      The dexamethasone suppression test as a discriminator among subtypes of psychotic patients.
      • 72
      Urinary free cortisol in psychotic depression
      • R. Anton
      • Psychology, Medicine
      • Biological Psychiatry
      • 1987
      • 67
      Psychotic depression: a separate entity?
      • 77
      The Clinical and Neuroendocrine Features of Psychotic Depression
      • 117
      Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486).
      • 103
      The endocrine effects of long-term treatment with mifepristone (RU 486).
      • 80